Urology news for Tuesday, October 20, 2026

Top 5 in urology

FDA accepts NDA for UGN-103 in recurrent low-grade intermediate-risk NMIBC FDA action · CancerNetwork · 2026-10-19
The FDA has accepted a new drug application for UGN-103 for recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer; a decision is pending.
Why it matters: An approval could add another intravesical option for this NMIBC risk category.
More Bladder cancer news
NEITHER study finds inconsistent triage between NICE and EAU surveillance guidance in NMIBC Study · UroToday · 2026-10-19
The NEITHER study compared NICE and EAU recommendations for surveillance of non-high-risk NMIBC and found inconsistent triage, cost, and reliability between the two frameworks.
Why it matters: Highlights that guideline discordance between major societies can lead to variable surveillance intensity and resource use for the same patient.
More Bladder cancer news
Delphi study defines 15 core entrustable professional activities for urology residency graduates Study · Urology · 2026-10-16
A national Delphi panel of academic urology educators distilled 242 candidate activities into 15 core EPAs that urology residents should perform independently by graduation, covering evaluation, medical management, and a narrower set of procedures.
Why it matters: Provides a competency-based framework that may inform future resident assessment and milestone evaluation in urology training programs.
UK Biobank data show kidney stone incidence rises linearly with age, challenging prior assumptions Retrospective · J Endourol · 2026-10-15
Among nearly 495,000 UK Biobank participants followed 2010-2022, kidney stone incidence rose progressively with age (39.4 to 150.5 per 100,000 person-years from age 46 to 80), contrasting with the traditional view that risk peaks in middle age.
Why it matters: Challenges the view that stone risk peaks in midlife; whether prevention strategies should target older adults warrants further study.
More Endourology and stone disease news
Phase 2a trial opens testing two dosing regimens of 177Lu-TLX250 in advanced clear cell RCC Trial opening · ClinicalTrials.gov · 2026-10-13
A multicenter phase 2a study (planned enrollment 40) will evaluate two dosing regimens of the CAIX-targeted radioligand therapy 177Lu-TLX250 in relapsed or recurrent clear cell renal cell carcinoma, aiming to determine a recommended phase 3 dose.
Why it matters: CAIX-targeted radioligand therapy represents an emerging treatment approach for clear cell RCC, a tumor type with few radiopharmaceutical options to date.
More Kidney cancer news

Prostate cancer news

Q-TWiST analysis of ARASENS examines quality-adjusted survival with darolutamide regimen Retrospective · UroToday · 2026-10-19
A Q-TWiST analysis of the ARASENS trial examined quality-adjusted time without symptoms or toxicity in patients with metastatic hormone-sensitive prostate cancer treated with darolutamide plus ADT and docetaxel. Specific results and the exact study design are not detailed in the available source text.
Why it matters: This Q-TWiST analysis of ARASENS raises questions about quality-adjusted survival with darolutamide, but details are limited pending full results.
Cost-effectiveness analysis examines adding enzalutamide in ENZAMET phase 3 trial Phase 3 RCT · UroToday · 2026-10-19
A secondary within-trial cost-effectiveness analysis of the ENZAMET phase 3 RCT compared adding enzalutamide versus standard nonsteroidal antiandrogens in metastatic hormone-sensitive prostate cancer receiving first-line ADT.
Why it matters: Offers economic context for a guideline-endorsed combination, though it is a secondary endpoint analysis rather than the trial's primary efficacy result.
Phase 3 trial launches comparing BNT324 to docetaxel in mCRPC Trial opening · NCI · 2026-10-16
A newly registered phase 3 trial will compare the antibody-drug conjugate BNT324 against docetaxel chemotherapy in metastatic castration-resistant prostate cancer. No efficacy or safety results are available yet.
Why it matters: A new ADC could offer an alternative to chemotherapy in mCRPC if the trial is positive.
Review: AI-based GP4 volume quantification not yet ready to refine active surveillance criteria Review · Eur Urol Focus · 2026-10-17
This review discusses how Gleason pattern 4 volume predicts outcomes in intermediate-risk prostate cancer but measurement is inconsistent; AI-based digital pathology tools show promise but remain insufficiently validated for clinical decisions.
Why it matters: Clinicians should be aware that AI-based GP4 quantification tools are investigational and not yet validated for guiding active surveillance eligibility.
Study finds wide variation in PSA referral thresholds across NHS trusts in England Study · BJU Int · 2026-10-17
This study examines variability in the PSA level thresholds used by NHS trusts across England to trigger referral for suspected prostate cancer, highlighting inconsistency in early detection pathways.
Why it matters: Inconsistent referral thresholds could contribute to inequitable access to timely prostate cancer diagnosis.
Higher baseline GDF15 linked to shorter survival in abiraterone-treated mCRPC in small cohort Retrospective · Clin Genitourin Cancer · 2026-10-17
In a retrospective analysis of 28 mCRPC patients on abiraterone, higher baseline serum GDF15 was independently associated with shorter overall survival (median 12 vs 42 months by median split) after adjustment for PSA50 response and visceral metastases.
Why it matters: Raises GDF15 as a candidate prognostic biomarker in mCRPC, though validation in larger prospective cohorts is needed before clinical use.
Randomized phase 2: talazoparib-enzalutamide met PSA goal but showed no clear benefit over enzalutamide alone RCT · Nat Med · 2026-10-16
In 54 men with high-volume mHNPC unselected for HRR mutations, talazoparib plus enzalutamide met its prespecified single-arm PSA response threshold (73% vs prespecified goal, P<0.001). The exploratory comparison to enzalutamide alone (64.7%) was not significant (P=0.54). Combination therapy caused more grade 3+ toxicity (68% vs 35%) including two fatal myeloid neoplasms.
Why it matters: Adding PARP inhibition to ARPI therapy in biomarker-unselected hormone-naive patients met its primary endpoint but showed no clear efficacy edge over enzalutamide alone in exploratory comparison, with added toxicity.
Meta-analysis: metformin added to ADT improves metabolic markers but not survival, per STAMPEDE-inclusive pooled data Meta-analysis · Prostate Cancer Prostatic Dis · 2026-10-16
Pooling six RCTs (2,415 patients, 78% from STAMPEDE), metformin plus ADT modestly reduced waist circumference, HbA1c, and fasting glucose at 12 months, while STAMPEDE itself showed no overall survival benefit (HR 0.91, p=0.15).
Why it matters: Clarifies that metformin may help offset ADT-associated metabolic syndrome but should not be used with an expectation of oncologic benefit.
Meta-analysis finds lower detected prostate cancer incidence in transgender women on hormone therapy Meta-analysis · Eur Urol Oncol · 2026-10-16
Pooled analysis of 54,342 transgender women on gender-affirming hormone therapy found a standardized incidence ratio of 0.224 versus cisgender men, but grade/stage data came from fewer than 40 cases with no matched comparison group.
Why it matters: Suggests GAHT may lower detectable prostate cancer risk, but evidence certainty is very low and should not change individualized screening discussions.
Focal salvage HDR brachytherapy shows low acute toxicity in phase I/II trial for radiorecurrent prostate cancer Phase 1-2 · J Clin Oncol · 2026-10-15
In the 62-patient F-SHARP phase I/II trial of dose-escalated focal salvage HDR brachytherapy after prior radiotherapy, no acute grade 3 toxicity occurred (2 patients had late grade 3 toxicity) and 3-year biochemical PFS was 62.7%. Among 31 patients with genomic classifier data, all 4 with scores above 0.85 experienced recurrence, suggesting a possible biomarker for risk stratification.
Why it matters: Suggests focal salvage HDR brachytherapy has low acute toxicity for radiorecurrent disease; the genomic classifier signal (4 patients) is exploratory.

Bladder cancer news

Active surveillance explored as option after neoadjuvant chemo for muscle-invasive bladder cancer Study · Renal & Urology News · 2026-10-19
A report examines whether active surveillance may be feasible for select patients who respond well to neoadjuvant chemotherapy for muscle-invasive bladder cancer, as an alternative to immediate cystectomy or radiation.
Why it matters: Raises the question of whether bladder-preserving surveillance could apply more broadly, but requires prospective validation before practice change.
Review outlines emerging combination strategies for BCG-unresponsive NMIBC beyond cystectomy Review · Nat Rev Urol · 2026-10-17
This review summarizes biological rationale and ongoing clinical strategies combining intravesical chemotherapy, BCG, immunotherapy, gene therapy and radiotherapy as bladder-preserving alternatives to cystectomy in BCG-unresponsive NMIBC.
Why it matters: Provides a framework for understanding the growing landscape of bladder-sparing combination therapies competing with cystectomy in BCG-unresponsive disease.
FDA expands Anktiva approval to papillary-only BCG-unresponsive bladder cancer FDA approval · BioPharm International · 2026-10-15
FDA broadened the approval of nogapendekin alfa inbakicept (Anktiva, N-803) to include patients with papillary-only BCG-unresponsive non-muscle invasive bladder cancer, expanding its prior approval for CIS.
Why it matters: Gives clinicians an added intravesical option for BCG-unresponsive papillary disease, an area with limited bladder-sparing alternatives.
BOND-003 cohort C: cretostimogene shows cystectomy-free survival in BCG-unresponsive NMIBC with CIS Phase 1-2 · UroToday · 2026-10-16
A conference presentation reported cystectomy-free survival results for intravesical cretostimogene grenadenorepvec in patients with high-risk BCG-unresponsive NMIBC with carcinoma in situ, from the phase 3 BOND-003 trial cohort C.
Why it matters: Adds to the evidence base for an investigational oncolytic virus therapy as a bladder-sparing option in BCG-unresponsive CIS, from a single-arm phase 3 cohort.
BOND-003 Cohort P: single-arm study of cretostimogene in papillary-only BCG-unresponsive NMIBC Phase 1-2 · UroToday · 2026-10-16
UroToday previewed an AUA 2026 presentation titled Topline Results from BOND-003 Cohort P, a multinational single-arm study of intravesical cretostimogene grenadenorepvec in high-risk, papillary-only, BCG-unresponsive NMIBC. The source provides only the abstract title; no outcome data are reported here.
Why it matters: Adds pipeline context in the BCG-unresponsive papillary-only NMIBC space, but no efficacy or safety data are available from this source yet.
CORE-008 cohort A: Phase 2 PK/PD data on intravesical cretostimogene in BCG-naive high-risk NMIBC Phase 1-2 · UroToday · 2026-10-16
A Phase 2 study (CORE-008 cohort A) presented clinical and pharmacokinetic/pharmacodynamic insights on intravesical cretostimogene grenadenorepvec in patients with high-risk BCG-naive NMIBC, as announced for presentation at AUA 2026. Specific efficacy and safety data were not detailed in this source.
Why it matters: Early Phase 2 PK/PD data on an investigational intravesical gene therapy for BCG-naive high-risk NMIBC, to be presented at AUA 2026; details not yet available.
Meta-analysis assesses perioperative immunotherapy in cisplatin-eligible MIBC Meta-analysis · UroToday · 2026-10-14
A meta-analysis of randomized controlled trials evaluates perioperative immune-based treatment regimens in cisplatin-eligible muscle-invasive bladder cancer.
Why it matters: Synthesizes evidence across trials on an increasingly used treatment approach in MIBC.
Multi-institution cohort reports outcomes of gemcitabine/docetaxel for BCG-unresponsive NMIBC Prospective · Eur Urol Focus · 2026-10-14
In 63 patients with BCG-unresponsive NMIBC treated with sequential gemcitabine/docetaxel, 12-month high-grade recurrence-free survival was 68.1% and 12.7% underwent radical cystectomy; BCG-refractory disease had higher recurrence risk than early-relapsing disease.
Why it matters: Adds prospective multi-institutional data supporting intravesical gemcitabine/docetaxel as a bladder-sparing option for BCG-unresponsive NMIBC.

Kidney cancer news

Meta-analysis: neoadjuvant therapy enables partial nephrectomy in 80% of selected RCC cases Meta-analysis · Clin Genitourin Cancer · 2026-10-20
A systematic review and single-arm meta-analysis of 34 studies found pooled rates of 80% for achieving partial nephrectomy, 32% objective response, and 11% pathologic complete response after neoadjuvant systemic therapy in localized/locally advanced RCC, with grade 3+ treatment-related adverse events in 28%.
Why it matters: Suggests neoadjuvant therapy may help enable nephron-sparing surgery in select RCC patients, though evidence certainty was low given the single-arm design.
Japanese database: no sharp 4-cm cutoff for PN selection; safety signal beyond 5 cm needs caution Retrospective · Clin Genitourin Cancer · 2026-10-17
Retrospective study of 36,015 T1 RCC patients across 941 Japanese hospitals found tumor size had a continuous, near-linear inverse association with odds of partial nephrectomy selection, with no distinct inflection at 4 cm. Among PN cases, adjusted odds of 30-day complication-free survival decreased with size up to about 5 cm, then appeared to plateau, a finding the authors say warrants cautious interpretation.
Why it matters: Hypothesis generating: practice data show no sharp 4-cm cutoff in partial nephrectomy selection, but the database lacks nephrometry and surgeon experience.
Delay beyond 3 months to partial nephrectomy linked to higher cancer mortality in younger patients Retrospective · Clin Genitourin Cancer · 2026-10-16
SEER analysis of 8,947 patients with 2-4 cm RCC: after matching, time to partial nephrectomy over 3 months was associated with higher cancer-specific mortality in patients 67 or younger (HR 1.62), but not in older patients; the effect was largest at 55 or younger.
Why it matters: Hypothesis generating. The association appears only in patients 67 or younger, not in older patients, and SEER cannot distinguish planned surveillance from treatment delay. Prospective data (e.g., DISSRM) show delayed intervention for small renal masses does not compromise cancer outcomes.
Phase 2 trial: neoadjuvant radiation before IVC thrombectomy for RCC appears feasible Phase 1-2 · JAMA Oncol · 2026-10-16
Single-center prospective phase 2 nonrandomized trial gave neoadjuvant stereotactic ablative radiotherapy to IVC tumor thrombus before nephrectomy/thrombectomy in 23 patients with RCC; 22 completed surgery and 21 were evaluable for the primary 1-year recurrence-free survival endpoint, compared with a prespecified historical surgery-alone benchmark of 55.7%.
Why it matters: Offers a potential neoadjuvant strategy for a high-risk, technically challenging RCC subgroup with IVC tumor thrombus lacking established local therapies, pending larger confirmatory studies.

Upper tract urothelial carcinoma news

UroVysion shows modest sensitivity but high PPV for UTUC in cytology-negative patients Retrospective · World J Urol · 2026-10-20
In a retrospective study of 1,256 patients with upper tract lesions and negative urinary cytology, UroVysion FISH had 66.9% sensitivity, 82.7% specificity, and 94.0% PPV for UTUC, and was associated with high-grade disease, lymphovascular invasion, and muscle invasion.
Why it matters: Raises the question of UroVysion as an adjunct when cytology is negative, though its low NPV limits its use for ruling out UTUC.
TROP-2 expression stays high in UTUC regardless of prior chemotherapy, unlike NECTIN-4 Retrospective · Eur Urol Open Sci · 2026-10-18
In 141 resected UTUC specimens, NECTIN-4 positivity was much lower after prior chemotherapy (9.3% vs 47% treatment-naive), while TROP-2 positivity remained near universal in both groups (97% vs 100%).
Why it matters: Suggests TROP-2 may be a more reliable ADC target than NECTIN-4 in UTUC patients previously treated with chemotherapy.
FDG-PET/CT upstages 22% of high-risk UTUC cases beyond CT, changing treatment in 21% Retrospective · BJU Int · 2026-10-15
In a 203-patient cohort with suspected high-risk UTUC, adding FDG-PET/CT to CT led to clinically relevant stage migration in 22% of patients and altered treatment recommendations in 21%, with higher sensitivity for nodal metastases than CT (74% vs 33%).
Why it matters: FDG-PET/CT may refine staging and treatment selection in high-risk UTUC beyond conventional CT imaging.
Surgical delay of 43+ days to nephroureterectomy linked to worse overall survival in UTUC Retrospective · Clin Genitourin Cancer · 2026-10-07
In 435 patients with upper tract urothelial carcinoma, waiting 43 days or more from diagnosis to radical nephroureterectomy was associated with worse overall survival (HR 1.43) after inverse probability weighting, though cancer-specific and recurrence-free survival differences were not statistically significant.
Why it matters: Adds to evidence that timely surgery after UTUC diagnosis may matter, relevant to scheduling and referral pathways.
CT urography and cytology miss most recurrences during UTUC endoscopic surveillance Retrospective · BJU Int · 2026-09-30
In a two-center study of 133 patients undergoing kidney-sparing endoscopic treatment for UTUC, combined CT urography and cytology avoided about 69% of surveillance ureteroscopies but missed nearly 65% of recurrences, with cytology alone highly specific but poorly sensitive.
Why it matters: Suggests noninvasive imaging and cytology cannot safely replace ureteroscopy for UTUC surveillance despite reducing procedure burden.
Meta-analysis: ureteroscopic biopsy forceps yield ~85% diagnostic rate in UTUC, no device superior Meta-analysis · J Endourol · 2026-09-29
Pooling 19 studies and over 1,700 biopsies, flexible ureteroscopy forceps achieved 84.6% diagnostic yield and 78.8% grade concordance in upper tract urothelial carcinoma, with over half of apparently non-muscle-invasive tumors upstaged at nephroureterectomy, and no forceps design outperforming others.
Why it matters: Reinforces that ureteroscopic biopsy alone should not be relied upon to exclude muscle-invasive UTUC when planning kidney-sparing therapy.

Testicular cancer news

Post-chemo RPLND for seminoma: 84% 5-yr survival in viable seminoma cases, 27% relapsed overall Retrospective · J Urol · 2026-10-08
Retrospective multi-institutional study of 108 pure seminoma patients undergoing post-chemo RPLND for residual masses. Among those with viable seminoma on pathology, 5-year overall survival was 84%. Overall, 27% of patients relapsed and marker-negative progression independently predicted worse progression-free survival (p<0.001).
Why it matters: Retrospective data support EAU guidance on centralizing this technically demanding seminoma RPLND procedure, given its morbidity and relapse risk even with favorable survival in viable seminoma cases.
EAU panel recommends centralized care to improve testicular cancer outcomes Guideline · UroToday · 2026-09-25
A European Association of Urology guidelines panel report argues that treatment at higher-volume centers is associated with better outcomes for testicular cancer patients, supporting centralization of care.
Why it matters: Referral pathways and case volume may influence outcomes in a highly curable cancer where errors have long-term consequences.

Endourology and stone disease news

Transient apnoea during ureteroscopic lithotripsy speeds stone clearance RCT · BJU Int · 2026-10-19
In a 150-patient three-arm trial, transient apnoea during flexible ureteroscopic laser lithotripsy improved active lithotripsy efficiency versus regular ventilation and small tidal-volume ventilation, with shorter operative time and better surgeon-rated stability, though stone-free rates were similar across groups.
Why it matters: Suggests an anesthesia-based technique to reduce operative time without added bleeding/complication risk, worth discussing with anesthesia teams.
Evidence map charts rapid growth of suction ureteroscopy research, mostly retrospective and single-center Review · BJU Int · 2026-10-18
A systematic evidence map of 154 studies (2022-2026) on suction ureteric access sheaths and direct-in-scope suction found publications rose sharply, led by China, with retrospective comparative studies dominating and only 11 RCTs identified.
Why it matters: Highlights that despite growing adoption of suction-assisted ureteroscopy, high-quality randomized evidence remains limited.
Multicenter registry: direct in-scope suction achieves 93% stone-free rate in ureteroscopy Prospective · Eur Urol Open Sci · 2026-10-15
In a 540-patient prospective registry across 16 centers, flexible ureteroscopy using a direct in-scope suction device achieved an overall 30-day stone-free rate of 93% (71% zero-residual-fragment), with low major complication rates.
Why it matters: Provides real-world prospective efficacy and safety data for an emerging suction-assisted ureteroscopy technology.
Systematic review: SGLT2 inhibitors linked to lower stone risk than GLP-1 or DPP-4 drugs in diabetics Review · Transl Androl Urol · 2026-10-14
An EAU Endourology systematic review of six observational studies found SGLT2 inhibitor use was associated with lower incident and recurrent urolithiasis risk than GLP-1 receptor agonists (HR 0.51-0.69) or DPP-4 inhibitors (HR 0.33-0.84) in patients with diabetes.
Why it matters: Suggests antidiabetic drug class choice may carry incidental stone-prevention implications relevant to counseling diabetic stone formers.

BPH and male LUTS news

Mini-HoLEP improves early continence recovery versus standard HoLEP in RCT Prospective · Eur Urol Open Sci · 2026-10-19
In a 90-patient randomized trial, mini-HoLEP using a 22-Fr resectoscope reduced urinary incontinence at 1 month (22.2% vs 51.1%) and 2 months versus standard 26-Fr HoLEP, with no significant difference in long-term continence or complications.
Why it matters: Offers a technical modification that may speed early continence recovery after HoLEP without compromising long-term outcomes.
Butterfly Prostatic Retraction Device receives EU MDR certification for BPH Intl regulatory · Urology Times · 2026-10-13
The Butterfly Prostatic Retraction Device has received EU MDR certification for treatment of BPH, according to Urology Times.
Why it matters: Adds another minimally invasive device option to the European BPH treatment landscape.

Female pelvic medicine and neurourology news

FDA issues Class 2 recall of PNE Lead Implant Kit FDA action · FDA · 2026-10-17
FDA has classified a recall of a percutaneous nerve evaluation (PNE) lead implant kit as Class 2, a device category used in sacral neuromodulation testing for voiding dysfunction.
Why it matters: Urologists using PNE leads for sacral neuromodulation trials should check whether affected lots are in their inventory.

Reconstruction and trauma news

Meta-analysis: PAMORAs linked to faster bowel recovery after radical cystectomy Meta-analysis · Transl Androl Urol · 2026-10-14
A systematic review and meta-analysis found that adding peripherally acting mu-opioid receptor antagonists (alvimopan, naloxegol, methylnaltrexone) to enhanced recovery pathways after radical cystectomy was associated with shortened time to first flatus and improved postoperative GI recovery versus enhanced recovery alone, though certainty of evidence varied and data specific to cystectomy remain limited and…
Why it matters: Suggests PAMORAs may help reduce postoperative ileus after cystectomy, but evidence quality is variable and more robust data are needed before routine incorporation into enhanced recovery protocols.
Systematic review: incisional hernia after robotic prostatectomy varies widely, linked to extraction site Review · Eur Urol Open Sci · 2026-10-12
Across 16 mostly retrospective studies (56,661 patients), reported incisional hernia after minimally invasive radical prostatectomy ranged from 0.04% to 31%. Two comparative studies found lower rates with Pfannenstiel than periumbilical extraction, and three registry studies reported lower rates after open surgery than after MIRP. Evidence is limited by heterogeneous definitions and follow-up.
Why it matters: Observational data suggest specimen extraction site and surgical approach may influence incisional hernia risk after robotic prostatectomy, but evidence is heterogeneous and not yet definitive.
Augmentation cystoplasty shows durable urodynamic benefit over median 19 years in spinal cord injury Retrospective · BJU Int · 2026-10-10
In a retrospective cohort of 70 patients with spinal cord injury and refractory neurogenic bladder dysfunction, augmentation cystoplasty increased mean bladder capacity from 155 to 490 mL and reduced detrusor pressure from 72 to 19 cmH2O, with continence achieved in 67% over a mean 19-year follow-up; complications included urolithiasis (10%) and malignancy (4%).
Why it matters: Provides long-term reassurance on durability and complication rates for augmentation cystoplasty in a population with limited surgical alternatives.
Institutional experience improves 5-year outcomes for gender-affirming penile prosthesis Retrospective · J Sex Med · 2026-09-28
In a retrospective cohort of 473 patients undergoing first-time gender-affirming inflatable penile prosthesis insertion, cumulative institutional experience, single-cylinder implantation, and use of one device brand were linked to lower risk of subsequent surgery, with peak proficiency identified around case 311.
Why it matters: Highlights a long learning curve for gender-affirming IPP surgery, relevant for centers building or scaling these programs.
Novel laparoscopic technique described for refractory piriformis-related pelvic pain Retrospective · J Endourol · 2026-09-26
A retrospective series of 200 patients across multiple institutions describes a transgluteal laparoscopic piriformis muscle transection technique for chronic pelviperineal pain syndrome, reporting technical feasibility with low morbidity and short hospital stay.
Why it matters: Introduces a minimally invasive surgical option for a difficult-to-treat and underrecognized cause of chronic pelvic pain.

Men's health news

Meta-analysis quantifies modest, highly variable gains from penile augmentation procedures Meta-analysis · Int J Impot Res · 2026-10-18
Pooled data from 30 studies (2554 patients) showed girth increases of roughly 1.9-2.0 cm with fillers or grafts and length gains of 1.4-2.2 cm, but extreme heterogeneity and wide prediction intervals mean individual outcomes vary greatly.
Why it matters: Provides realistic outcome ranges for counseling patients considering penile augmentation, emphasizing uncertainty over pooled averages.

Pediatric urology news

AAP updates recommendations on management of UTI in children under age 5 Guideline · Renal & Urology News · 2026-10-16
The American Academy of Pediatrics has issued updated guidance on diagnosis and management of urinary tract infection in children under 5 years old.
Why it matters: Pediatric UTI guidance affects urology referral thresholds and imaging decisions for febrile young children.
Higher chemotherapy dose and testicular radiation linked to abnormal pubertal hormone patterns in childhood cancer survivors Retrospective · JAMA Netw Open · 2026-10-10
In a cohort of 221 male childhood cancer survivors, cumulative alkylating chemotherapy dose and testicular radiotherapy above 1 Gy were associated with dose-dependent elevations in pubertal FSH levels, a marker of impaired gonadal function.
Why it matters: Suggests cumulative alkylator and testicular radiation dose track with gonadal dysfunction, which may help identify survivors for earlier fertility discussions.
Temporary vesicostomy cuts early complications after pediatric bladder augmentation Retrospective · Neurourol Urodyn · 2026-10-01
In 168 children undergoing ileocystoplasty with catheterizable stoma, temporary incontinent vesicostomy was associated with markedly lower rates of anastomotic leakage, stoma obstruction, and febrile UTI (2.3% vs 28.6% overall complication rate), without affecting 24-month continence or bladder dynamics.
Why it matters: Raises the question of whether temporary vesicostomy reduces early complications after augmentation; retrospective comparison cannot exclude selection differences.
Review proposes risk-stratified framework for observation versus treatment of pediatric varicocele Review · Nat Rev Urol · 2026-10-01
This narrative review synthesizes evidence on pediatric varicocele management, noting lack of consensus, and proposes a risk-stratified model using grade, testicular volume asymmetry, and semen/hormonal parameters to guide observation versus early intervention.
Why it matters: Offers a practical framework for a common but controversial pediatric urology decision where high-quality outcome data are limited.
New reference curves define expected residual hydronephrosis after pyeloplasty Retrospective · World J Urol · 2026-09-27
In 566 renal units after pyeloplasty, postoperative APD reference curves were built from units without recurrence. Renal pelvic APD above the 90th centile curve was linked to a much higher reoperation rate (11.7% vs 0.8%).
Why it matters: Offers an objective benchmark to decide which children with residual postoperative dilation need closer follow-up versus reassurance.
Insurance status and timing linked to orchiectomy odds after testicular torsion in NY state Retrospective · J Pediatr Urol · 2026-09-27
Among 4,159 children with testicular torsion in New York State over 15 years, 26% underwent orchiectomy; government or self-pay insurance and presentation timing were associated with higher orchiectomy odds, with effects varying by age group.
Why it matters: Points to potential access or systems-level disparities affecting testicle salvage rates that may warrant institutional review.

More urology news

Randomized trial opens comparing ADC plus immunotherapy to chemo plus immunotherapy in unresectable high-risk NMIBC Trial opening · ClinicalTrials.gov · 2026-10-16
A new randomized phase 2 trial will compare an antibody-drug conjugate plus immunotherapy against immunotherapy plus chemotherapy in patients with extensive, transurethrally unresectable very-high-risk NMIBC. No results are available yet.
Why it matters: Addresses an unmet need for bladder-preserving options in patients who cannot undergo complete TURBT.
Phase 2 trial opens testing ivonescimab combinations in advanced clear cell RCC Trial opening · ClinicalTrials.gov · 2026-10-16
A new phase 2 trial will evaluate ivonescimab alone or combined with cadonilimab or ipilimumab in advanced clear cell renal cell carcinoma. No results are yet available.
Why it matters: Represents a new immunotherapy combination strategy under investigation for advanced RCC.
Phase 3 trial of deutenzalutamide plus ADT opens for high-risk biochemically recurrent prostate cancer Trial opening · ClinicalTrials.gov · 2026-10-15
A planned 1,044-patient randomized, double-blind, placebo-controlled phase 3 trial will test deutenzalutamide plus ADT versus placebo plus ADT in men with high-risk biochemical recurrence after definitive therapy for prostate cancer.
Why it matters: A new androgen receptor inhibitor is entering phase 3 testing in the biochemical recurrence setting, an area with evolving treatment intensification strategies.
AUA Census: fellowship-trained urologists rose from 40% to 46% over a decade, general urology fell Retrospective · Urology · 2026-10-06
Analysis of 2014-2024 AUA Census data shows fellowship-trained urologists increased from 40% to 46% while general urologists decreased from 63% to 54%, with subspecialists concentrated in academic and metropolitan settings.
Why it matters: Highlights a growing access gap as subspecialization trends toward academic, urban practice, with implications for rural and community urology coverage.

Loading today's edition…